Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6081-6090 Newer>

The Motley Fool December 15, 2009 Brian Orelli	Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again.
The Motley Fool December 15, 2009 Brian Orelli	It's Nice to Have Friends With Cash Array hits up Amgen for some much-needed cash.
The Motley Fool December 14, 2009 Rich Smith	This Just In: Upgrades and Downgrades Piper Jaffray plays a wrong note on Teva.
The Motley Fool December 14, 2009 Brian Orelli	Finally Released From an Extended Review The FDA finally approves extended-release Zyprexa.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool December 11, 2009 Brian Orelli	Gilead Gets the Experts on Its Side An advisory committee says yes after the FDA said no.
BusinessWeek December 10, 2009 Chad Terhune	A Hole in Health-Care Reform Over billing by medical-equipment suppliers, device makers, and drug companies has cost taxpayers billions. New legislation will do little to stem the tide.
BusinessWeek December 10, 2009	Policing Corporations Here are some selected settlements of federal cases involving allegations of health-care industry misconduct.
BusinessWeek December 10, 2009 Weintraub & Wechsler	The New Prominence of Comparative Drug Trials Pharmaceutical makers, once wary of head-to-head trials, now embrace them as marketing tools.
The Motley Fool December 10, 2009 Brian Orelli	A Tale of Two Lillys It was the best of times, it was the worst of times. Dickens could have been talking about Eli Lilly which has a tale of two cities all on its own.
<Older 6081-6090 Newer> Return to current articles.